MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, LIXT had $2,000,662 increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$2,000,662

Unit: Dollar
Cash Flow
2025-09-30
2025-06-30
Research and development costs
-0
Net loss
-1,980,398 -1,485,228
General and administrative costs
776,611 367,737
Common stock issued for services
44,711 -
Unrealized gain (loss) on digital assets
-182,887 -
Prepaid insurance
14,893 -6,301
Other prepaid expenses
-26,104 2,290
Accounts payable and accrued expenses
59,218 36,443
Research and development contract liabilities
-20,992 21,069
Advances on research and development contract services
-0
Net cash used in operating activities
-926,752 -1,055,968
Purchase of digital assets
2,637,360 -
Net cash used in investing activities
-2,637,360 -
Proceeds from sale of securities in registered direct offerings, net of offering costs
1,330,812 914,228
Proceeds from sale of securities in registered private placement, net of offering costs
4,178,162 -
Payment of deferred offering costs
-10,000
Exercise of common stock warrants
45,800 -
Net cash provided by financing activities
5,564,774 904,228
Net increase (decrease)
2,000,662 -151,740
Cash and cash equivalents at beginning of period
1,038,952 -
Cash and cash equivalents at end of period
2,887,874 -
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)